Economic aspects of empiric antibiotic therapy for febrile neutropenia in children with cancer

Elio Castagnola, Dimitri Paola, Raffaella Giacchino, Rossella Rossi, Claudio Viscoli

Research output: Contribution to journalArticle

Abstract

Several antibiotic regimens have been proposed worldwide for empiric treatment of febrile neutropenia in children with cancer, but none of them shows clear advantages in terms of clinical efficacy. Therefore, other parameters, including drug acquisition costs, should be considered in the selection of treatment. Children receive a 'fraction' of a standard daily dose, and this fraction is generally calculated on the basis of body weight; therefore, the cost of each day of therapy is determined by the packages available for each single drug. We calculated the acquisition costs of various drugs proposed for the empiric treatment of febrile neutropenia in children with cancer, and then we estimated the daily cost of therapy referred to different patient weights. In general, the combination regimen with ceftriaxone plus aminoglycoside turned out to be less expensive than other regimens (including monotherapy with third-generation cephalosporins or carbapenems).

Original languageEnglish
Pages (from-to)524-528
Number of pages5
JournalSupportive Care in Cancer
Volume6
Issue number6
DOIs
Publication statusPublished - Nov 1998

Keywords

  • Economic evaluation
  • Empiric antibiotic therapy
  • Febrile neutropenia

ASJC Scopus subject areas

  • Oncology
  • Nursing(all)

Fingerprint Dive into the research topics of 'Economic aspects of empiric antibiotic therapy for febrile neutropenia in children with cancer'. Together they form a unique fingerprint.

Cite this